Theravance Biopharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.01.24	Theravance Biopharma: Phase 4 PIFR-2 Study Fails To Meet Primary Endpoint (RTTNews)
13.11.23	Viatris, Theravance Report Positive Top-line Results From Phase III Trial For YUPELRI In China (RTTNews)
13.11.23	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
08.05.23	Theravance Biopharma Inc. Q1 Loss misses estimates (RTTNews)
28.09.22	Theravance Biopharma Announces Modified Dutch Auction Tender Offer - Quick Facts (RTTNews)
19.09.22	Theravance Biopharma Rises 6% On News Of Share Buyback (RTTNews)
19.09.22	Theravance To Buy Back $250 Mln Of Shares (RTTNews)
14.07.22	Theravance Shares Whipsaw After Deciding To Sell Royalty Rights Of GSK's Trelegy Ellipta (RTTNews)
14.07.22	Pre-market Movers: ARQQ, RAD, TBPH, ULCC, EGY… (RTTNews)
14.07.22	Royalty Pharma To Buy Royalty Interest In Trelegy Ellipta From Theravance And Innoviva (RTTNews)
15.09.21	Theravance Biopharma To Cut 75% Jobs, Board Size; To Focus On Respiratory Disease Portfolio (RTTNews)
15.09.21	Theravance Biopharma: Ampreloxetine Phase 3 Study In NOH Patients Fails To Meet Primary Goal (RTTNews)
24.08.21	Pre-market Movers: BXRX, CARA, HGBL, REKR, TBPH… (RTTNews)
23.08.21	Theravance Bio Stock Tanks Over 20% After Ulcerative Colitis Drug Trial Fails To Meet Primary Goals (RTTNews)
03.08.21	Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
20.07.21	Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021 (PR Newswire)
25.06.21	Pre-market Movers: FFHL, NKE, LPG, MRIN... (RTTNews)
21.06.21	Theravance Phase 2 Nezulcitinib Study Did Not Meet Primary Goal In Acute Lung Injury Due To COVID-19 (RTTNews)
21.06.21	Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19 (PR Newswire)
21.06.21	Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19 (PR Newswire)
10.11.18	Week Ahead In Pharmaceuticals: 13 Stocks To Watch (EIDX, NOVN, ZYME...) (RTTNews)
29.10.18	Biotech Stocks Facing FDA Decision In November (RTTNews)
11.10.18	Theravance, Mylan Report Positive New Data From Multiple Studies Of Yupelri (RTTNews)
08.10.18	Theravance Biopharma And Mylan To Present Data From Studies Of YUPELRI (RTTNews)
17.09.18	Theravance Reports Positive Data From Phase 3 Program For YUPELRI Solution (RTTNews)
15.09.18	Week Ahead In Pharmaceuticals: 7 Stocks To Watch (CMRX, VRNA, NITE...) (RTTNews)
12.09.18	FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. (RTTNews)
21.07.18	Week Ahead In Pharmaceuticals - 14 Stocks To Watch (LCI, INSY, TBPH...) (RTTNews)
06.06.18	Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 (PR Newswire)
29.05.18	Theravance Biopharma Highlights Submission of Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD (PR Newswire)
17.05.18	Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension (PR Newswire)
10.05.18	Theravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference (PR Newswire)
08.05.18	Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update (PR Newswire)
01.05.18	Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018 (PR Newswire)
25.04.18	Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients (PR Newswire)
23.04.18	Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference (PR Newswire)
20.04.18	Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (PR Newswire)
19.04.18	Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients (PR Newswire)
17.04.18	Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference (PR Newswire)
21.03.18	Theravance Biopharma to Present at the 17th Annual Needham Healthcare Conference (PR Newswire)
27.02.18	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update (PR Newswire)
23.02.18	Aerkomm Inc. Appoints James J. Busuttil to its Board of Directors (PR Newswire)
20.02.18	Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018 (PR Newswire)
15.02.18	Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta (PR Newswire)
08.02.18	MobileIron Announces Strong Fourth Quarter 2017 Results (PR Newswire)
08.02.18	TBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back Again (RTTNews)
07.02.18	Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases (PR Newswire)
30.01.18	ARDM Chokes, ABEO On Track, MASI Gets FDA Nod, ALBO Up 50% YTD (RTTNews)
29.01.18	Theravance Biopharma And Mylan Announce FDA Acceptance Of NDA For Revefenacin (RTTNews)
29.01.18	Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Theravance Biopharma Inc When Issued

Aktien Top/Flop

Meistgelesene Nachrichten